Results 41 to 50 of about 27,995 (239)

Pregabalin dispensing patterns in Amman-Jordan: An observational study from community pharmacies

Saudi Pharmaceutical Journal, 2018
Objectives: Pregabalin is currently approved for the treatment of epilepsy, generalized anxiety disorder, neuropathic pain and fibromyalgia. Rising attention to the abuse liability of pregabalin causing addictive behaviors is partially based on case ...
Amneh Al-Husseini, Rana Abu-Farha, Mayyada Wazaify, Marie Claire Van Hout   +3 more
doaj   +1 more source

Nickel‐Catalyzed Three‐Component Difluoroalkylation‐Amination for the Direct Access to Anti‐Inflammatory β‐Difluoroalkyl Amines

Advanced Science, EarlyView.
A nickel‐catalyzed three‐component reductive fluoroalkylation‐amination strategy of N‐vinylamides for the direct access to the α‐amidyl‐β‐difluoroalkyl amines was reported here. The synthetic method features with broad substrate scope, mild conditions, high functional group tolerance, and convenience to handle.
Chang Xu, Fangting Ma, Fan Ding, Luyan Wang, Yunxi Li, Yunzhi He, Xingang Zhang, Siyu He, Dandan Liu   +8 more
wiley   +1 more source

Robots and Minimal, Physics‐Informed Features: A Hybrid Framework for Enzyme Catalysis

Advanced Science, EarlyView.
Robotic experimentation and physics‐informed machine learning combine to predict enzyme substrate scope. With a handful of interpretable features derived from docking and quantum mechanics calculations, our model rivals descriptor‐heavy AI approaches and extrapolates to unseen substrates and enzyme classes.
Natalia Onishchenko, Eric S. Larsen, Govind Paneru, Kisung Lee, Diana V. Kolygina, Yankai Jia, Elizabeth Maria Clarissa, Wai‐Shing Wong, Bartosz A. Grzybowski   +8 more
wiley   +1 more source

Pregabalin prescribing patterns in Australian general practice, 2012–2018: a cross-sectional study

BJGP Open, 2021
Background: In 2013 pregabalin was subsidised by Australia’s Pharmaceutical Benefits Scheme (PBS) for neuropathic pain. Since the subsidy, pregabalin prescribing has been increasing in Australia and so has related harm.
Andrea L Schaffer, Doreen Busingye, Kendal Chidwick, Jonathan Brett, Suzanne Blogg   +4 more
doaj   +1 more source

Current practice and guideline adherence in renal dose adjustment for patients with chronic kidney disease: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims To quantify prescribing adherence to renal dosing recommendations in adults with chronic kidney disease (CKD; Stage 3 and above) and to evaluate the clinical consequences of non‐adherence. Methods This systematic review and meta‐analysis was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025620883).
Hager ElGeed, Ahmed Tehemar, Mohamed Gasimelseed, Ahmed Gharaibeh, Muhammad Abdul Hadi, Kazeem Yusuff, Amani Zidan, Ahmed Awaisu   +7 more
wiley   +1 more source

Understanding pregabalin misuse and dependence: Insights from a North Indian addiction treatment center

Indian Journal of Psychiatry
Background: Pregabalin, approved for various medical conditions, has shown increasing misuse potential globally. However, limited research exists on pregabalin dependence in India.
Abhishek Ghosh, Shantanu Shukla, Mondeep Dhankar, Shalini S. Naik, BN Subodh, Debasish Basu   +5 more
doaj   +1 more source

Involvement of the dopaminergic system in the reward-related behavior of pregabalin

Scientific Reports, 2021
There has been an increase in cases of drug addiction and prescription drug abuse worldwide. Recently, pregabalin abuse has been a focus for many healthcare agencies, as highlighted by epidemiological studies.
Yusuf S. Althobaiti, Farooq M. Almutairi, Fahad S. Alshehri, Ebtehal Altowairqi, Aliyah M. Marghalani, Amal A. Alghorabi, Walaa F. Alsanie, Ahmed Gaber, Hashem O. Alsaab, Atiah H. Almalki, Alqassem Y. Hakami, Turki Alkhalifa, Ahmad D. Almalki, Ana M. G. Hardy, Zahoor A. Shah   +14 more
doaj   +1 more source

Translational development of crisugabalin for neuropathic pain

British Journal of Clinical Pharmacology, EarlyView.
Abstract Crisugabalin (HSK16149) is a next‐generation α2δ ligand developed to preserve the mechanistic rationale of gabapentinoids while refining target engagement and exposure‐related tolerability constraints. We performed a translational review of molecular/structural studies, in vivo pharmacology and behavioural safety assessments, phase I clinical ...
Rafael Batista João, Jilly Octoria Tagore Chan, Luísa Mendes Araújo, André Batista João, Raquel Mattos Filgueiras, Paulo César Ragazzo   +5 more
wiley   +1 more source

Pregabalin abuse among patients with opioid use disorders may increase the severity of withdrawal symptoms: a single-center, case-control study

Psychiatry and Clinical Psychopharmacology, 2019
OBJECTIVE: Opioid addiction is a disease that is increasing in our country, Turkey, and around the world, which it is difficult to treat in medical, social, and economic terms.
Özlem Çıtak Ekici, Volkan Şahiner, Gamze Erzin, Davut Ocak, Şafak Yalçın Şahiner, Erol Göka   +5 more
doaj   +1 more source

Assessing kidney function for drug dosing in critical illness

British Journal of Clinical Pharmacology, EarlyView.
Kidney‐function assessment supports drug dosing in critical illness but does not directly measure drug clearance. Reduced creatinine generation, fluid shifts and rapidly changing filtration can make creatinine‐based estimates misleading, whereas genuinely augmented renal clearance can cause insufficient drug exposure. These processes can coexist.
Ming‐Shen Lin, Kuo‐Fan Liao
wiley   +1 more source